Skuteczne odstawienie nilotynibu po niepowodzeniu terapii imatynibem

Successful treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKI) is nowadays likely to result in near-normal life expectancy. Nowadays, the treatment-free remission (TFR) is becoming more and more often a therapeutic goal for both hematologist and his patient. TKI discontinuation and maintenance of TFR is feasible in circa 40–50% of CML patients who achieved stable deep molecular response (DMR). Here, we present a patient with CML, who was switched to nilotinib due to imatinib therapy failure. After a few years of sustaining DMR nilotinib was discontinued. One year since this decision, the patient has remained in the TFR.